Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 325-326

  Dubrey, Simon W ^a,c   Holt, David W ^b   Banner, Nicholas ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

^c HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; Heart transplantation; Monitoring levels; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL;

ADULT; CARDIOMYOPATHY, DILATED; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID;

EID: 0033040712     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00013     Document Type: Article

References (5)

1. Meisser BM, Pfeiffer M, Jagiello-Kraatz M, et al. Mycophenolate mofetil dose adjustments based on trough levels improve outcome after heart transplantation significantly [abstract]. J Heart Lung Transplant 1998;17:85.
2. Sanquer S, Breil M, Baron C, Dahmane D, Astier A, Lang P. Trough blood concentrations in long-term treatment with mycophenolate mofetil [letter]. Lancet 1998;351:1557.
3. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
4. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38:268-75.
5. Taylor DO, Douglas Ensley R, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): Preclinical, clinical and three-year experience in heart transplantation. J Heart Lung Transplant 1994;13:571-82.